Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 20/20 | 0.78 |
| ▸ | EZH1 | Q92800 | 3/20 | 0.69 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.63 |
| ▸ | EED | O75530 | 1/20 | 0.63 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.63 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.63 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.63 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.63 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.63 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.63 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12684069 | 1.00 | EZH2 (0.78) | EZH2EZH1NR1I2EEDABCB11 | |
| SCHEMBL19391445 | 0.94 | EZH2 (0.69) | EZH2EZH1 | |
| SCHEMBL16517927 | 0.94 | EZH2 (0.68) | EZH2EZH1 | |
| SCHEMBL12684073 | 0.93 | EZH2 (0.67) | EZH2EZH1 | |
| SCHEMBL12498927 | 0.92 | EZH2 (0.67) | EZH2EZH1 | |
| SCHEMBL12499081 | 0.92 | EZH2 (0.66) | EZH2EZH1 | |
| SCHEMBL12684373 | 0.91 | EZH2 (0.64) | EZH2EZH1 | |
| SCHEMBL12684409 | 0.91 | EZH2 (0.66) | EZH2EZH1 | |
| SCHEMBL12684040 | 0.91 | EZH2 (0.71) | EZH2EZH1 | |
| SCHEMBL12684479 | 0.91 | EZH2 (0.65) | EZH2EZH1NR1I2EEDABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 464 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636283-B2 | Inhibition of PRC2 subunits to treat eye disorders | FONDATION ASILE DES AVEUGLES (CH) | 2026-05-26 | — | — | US | claimed |
| WO-2026102034-A1 | COMPOSITIONS AND METHODS FOR GENETIC AND EPIGENETIC MODULATION | JUNIPERO THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | claimed |
| EP-4048260-B1 | COMBINATION OF SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR USE IN TREATING A HEMATOLOGICAL MALIGNANCY | CELGENE CORP (US) | 2026-03-11 | — | — | EP | claimed |
| US-12571049-B2 | Therapeutic treatment of select diffuse large B cell lymphomas exhibiting distinct pathogenic mechanisms and outcomes | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-03-10 | — | — | US | claimed |
| EP-4684836-A2 | COMBINATIONS OF LSD1 INHIBITORS FOR USE IN THE TREATMENT OF NEOPLASTIC DISEASES | Oryzon Genomics, S.A. (ES) | 2026-01-28 | — | — | EP | claimed |
| US-12529091-B2 | ATAC-array for prediction of disease-free survival in pancreatic cancer | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2026-01-20 | — | — | US | claimed |
| EP-4667458-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING SOS1 INHIBITOR AND ANTICANCER DRUG | Kanaph Therapeutics Inc. (KR) | 2025-12-24 | — | — | EP | claimed |
| EP-4658687-A1 | IMMUNE CHECKPOINT BLOCKADE THERAPY FOR TREATING STAPHYLOCOCCUS AUREUS INFECTIONS | University of Rochester (US) | 2025-12-10 | — | — | EP | claimed |
| US-20250352551-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | CELGENE CORPORATION | 2025-11-20 | — | — | US | claimed |
| US-12472196-B2 | Use of DNMT inhibitor | OHARA PHARMACEUTICAL CO., LTD. (JP) | 2025-11-18 | — | — | US | claimed |
| EP-4048668-A1 | METHODS FOR TREATING A HEMATOLOGICAL CANCER AND THE USE OF COMPANION BIOMARKERS FOR 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE | CELGENE CORPORATION (US) | 2022-08-31 | — | — | EP | claimed |
| EP-4048260-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | Celgene Corporation (US) | 2022-08-31 | — | — | EP | claimed |
| US-20220193056-A1 | COMPOSITIONS AND METHODS OF TREATING PIK3CA HELICAL DOMAIN MUTANT CANCERS | CASE WESTERN RESERVE UNIVERSITY | 2022-06-23 | — | — | US | claimed |
| WO-2022125725-A1 | COMPOSITIONS AND METHODS FOR TREATING WNT-DRIVEN CANCER | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-06-16 | — | — | WO | claimed |
| EP-3995830-A1 | METHOD OF PROGNOSIS OF AN INDIVIDUAL HAVING MULTIPLE MYELOMA TO BE SENSITIVE TO A TREATMENT | Centre national de la recherche scientifique (FR) | 2022-05-11 | — | — | EP | claimed |
| EP-3990444-A1 | USE OF INHIBITORS OF ENHANCER OF ZESTE HOMOLOG 2 | The Board of Regents of The University of Texas System (US) | 2022-05-04 | — | — | EP | claimed |
| CN-114423438-A | Use of DNMT inhibitors | 大原药品工业株式会社 | 2022-04-29 | — | — | CN | claimed |
| US-11298328-B2 | Sensorineural hair cell differentiation | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2022-04-12 | — | — | US | claimed |
| WO-2022042527-A1 | SMALL-MOLECULE DRUG FOR TREATING DISEASES RELATED TO INNER EAR AND INTESTINAL EPITHELIAL TISSUE INJURIES | 北京大学 | 2022-03-03 | — | — | WO | claimed |
| CN-114085803-A | Establishment of organoid culture systems with regenerative properties | 北京大学 | 2022-02-25 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12571049-B2 | Therapeutic treatment of select diffuse large B cell lymphomas exhibiting distinct pathogenic mechanisms and outcomes | BCL6, BCL3, BCL6B | EZH2 25/4885EZH1 124/4885NR1I2 3618/4885 |
| US-20250352551-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | DOT1L, CARM1, EZH2 | EZH2 3/4885EZH1 107/4885NR1I2 2501/4885 |
| US-12636283-B2 | Inhibition of PRC2 subunits to treat eye disorders | EZH2, EZH1, EED | EZH2 1/4885EZH1 2/4885NR1I2 701/4885 |
| US-12529091-B2 | ATAC-array for prediction of disease-free survival in pancreatic cancer | ABCC1, EPCAM, ABCF2 | EZH2 582/4885EZH1 147/4885NR1I2 2510/4885 |
| US-12472196-B2 | Use of DNMT inhibitor | DNMT3L, DNMT3A, DNMT1 | EZH2 34/4885EZH1 134/4885NR1I2 2416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.